Showing results (621-630 of 651) with videos related to
Sort By:
Pageof 66
Nature Communications|August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell levelLukas John, Alexandra M Poos, Alexander Brobeil, et al.Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.Journal of Hematology & Oncology|May 13, 2022
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, et al.American Journal of Hematology|October 2, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA TrialKatja Sockel, Christoph Röllig, Anke Mütherig, et al.Nature Cancer|January 3, 2025
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signalingRoberto Würth, Elisa Donato, Laura L Michel, et al.Pageof 66